tj301
Peptideexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2017 (NCT03235752)
Timeline
Indications
Mechanism of action
- Interleukin-6ANTAGONIST
IL6 antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06515834 | Phase 1 | Jul 1, 2024 | Ferring |
| NCT06298032 | Phase 1 | Feb 20, 2024 | Ferring |
| NCT03235752 | Phase 2 | Sep 12, 2017 | Leading Pharma Llc, Sun Yat-Sen University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 2 | 2 | 1 | 2024 |
| Leading Pharma Llc | For profit | 1 | 1 | 1 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1